{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"acarbose\" outputclass=\"int-drug\">acarbose</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  acarbose  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acarbose</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"alogliptin\" outputclass=\"int-drug\">alogliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  alogliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alogliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"amiodarone\" outputclass=\"int-drug\">Amiodarone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Amiodarone   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiodarone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bezafibrate\" outputclass=\"int-drug\">Bezafibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bezafibrate   is predicted to   increase   the risk of hypoglycaemia when given with   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bezafibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of hepatotoxicity when given with</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   increases   the risk of hepatotoxicity when given with   glibenclamide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"canagliflozin\" outputclass=\"int-drug\">canagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  canagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">Ceftobiprole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ceftobiprole   is predicted to   increase   the concentration of   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"chloramphenicol\" outputclass=\"int-drug\">Chloramphenicol</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor blood glucose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Chloramphenicol   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises monitor blood glucose .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chloramphenicol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"ciprofibrate\" outputclass=\"int-drug\">Ciprofibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Ciprofibrate   is predicted to   increase   the risk of hypoglycaemia when given with   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"clarithromycin\" outputclass=\"int-drug\">Clarithromycin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Clarithromycin   is predicted to   slightly   increase   the exposure to   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clarithromycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"co-trimoxazole\" outputclass=\"int-drug\">Co-trimoxazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Co-trimoxazole   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Co-trimoxazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"dapagliflozin\" outputclass=\"int-drug\">dapagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  dapagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"dulaglutide\" outputclass=\"int-drug\">dulaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  dulaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dulaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"empagliflozin\" outputclass=\"int-drug\">empagliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  empagliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Empagliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"ertugliflozin\" outputclass=\"int-drug\">ertugliflozin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  ertugliflozin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ertugliflozin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"exenatide\" outputclass=\"int-drug\">exenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  exenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Exenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fenofibrate\" outputclass=\"int-drug\">Fenofibrate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fenofibrate   is predicted to   increase   the risk of hypoglycaemia when given with   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fenofibrate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"fluconazole\" outputclass=\"int-drug\">Fluconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Fluconazole   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Mild\" outputclass=\"int-message\">\n  <ph otherprops=\"fluvastatin\" outputclass=\"int-drug\">Fluvastatin</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Mild",
							"hasOrder": "1",
							"hasTextContent": "Fluvastatin   slightly   increases   the exposure to   glibenclamide .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"gemfibrozil\" outputclass=\"int-drug\">Gemfibrozil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of hypoglycaemia when given with</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Gemfibrozil   is predicted to   increase   the risk of hypoglycaemia when given with   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemfibrozil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"insulins\" outputclass=\"int-drug\">insulins</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  insulins  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Insulins</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">Leflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Leflunomide   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"letermovir\" outputclass=\"int-drug\">Letermovir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Letermovir   is predicted to   increase   the concentration of   glibenclamide .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Letermovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"linagliptin\" outputclass=\"int-drug\">linagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  linagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"liraglutide\" outputclass=\"int-drug\">liraglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  liraglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Liraglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"lixisenatide\" outputclass=\"int-drug\">lixisenatide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  lixisenatide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lixisenatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"metformin\" outputclass=\"int-drug\">metformin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  metformin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metformin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"miconazole\" outputclass=\"int-drug\">Miconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Miconazole   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Miconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"nateglinide\" outputclass=\"int-drug\">nateglinide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  nateglinide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nateglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"pioglitazone\" outputclass=\"int-drug\">pioglitazone</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  pioglitazone  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pioglitazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"repaglinide\" outputclass=\"int-drug\">repaglinide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  repaglinide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Repaglinide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   is predicted to   decrease   the exposure to   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"saxagliptin\" outputclass=\"int-drug\">saxagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  saxagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Saxagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"semaglutide\" outputclass=\"int-drug\">semaglutide</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  semaglutide  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Semaglutide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"sitagliptin\" outputclass=\"int-drug\">sitagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  sitagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sitagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfadiazine\" outputclass=\"int-drug\">Sulfadiazine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfadiazine   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadiazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfadoxine\" outputclass=\"int-drug\">Sulfadoxine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfadoxine   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfadoxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfamethoxazole\" outputclass=\"int-drug\">Sulfamethoxazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfamethoxazole   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfamethoxazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sulfinpyrazone\" outputclass=\"int-drug\">Sulfinpyrazone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sulfinpyrazone   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfinpyrazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"teriflunomide\" outputclass=\"int-drug\">Teriflunomide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Teriflunomide   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Teriflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"venetoclax\" outputclass=\"int-drug\">Venetoclax</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Venetoclax   is predicted to   increase   the exposure to   glibenclamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venetoclax</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph> and <ph otherprops=\"vildagliptin\" outputclass=\"int-drug\">vildagliptin</ph> can increase the risk of hypoglycaemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  glibenclamide  and  vildagliptin  can increase the risk of hypoglycaemia. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vildagliptin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2#bnf_i1557280722559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"voriconazole\" outputclass=\"int-drug\">Voriconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"glibenclamide\" outputclass=\"int-heading-drug\">glibenclamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Voriconazole   is predicted to   increase   the concentration of   glibenclamide .  Manufacturer advises use with caution and adjust dose .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Voriconazole</title>"
					}
				}
			],
			"hasSearchLabel": " Glibenclamide  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/glibenclamide-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Glibenclamide </title>"
			},
			"rdfs:label": "glibenclamide"
		}
	]
}